The Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, are joined by Charu Aggarwal, MD, MPH, to discuss recent lung cancer data updates from clinical trials presented at the 2023 ASCO Annual Meeting.
EP. 1: ADAURA: Overall Survival Analysis of Osimertinib in NSCLC
Charu Aggarwal, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data updates from the ADAURA trial, an overall survival analysis of osimertinib in non–small cell lung cancer (NSCLC).
EP. 2: KEYNOTE-789: Chemotherapy With or Without Pembrolizumab for TKI-Resistant Nonsquamous NSCLC
Following ASCO 2023, experts in oncology review recent data updates from KEYNOTE-789 on chemotherapy with or without pembrolizumab for TKI-resistant nonsquamous NSCLC.
EP. 3: KEYNOTE-671: Perioperative Use of Pembrolizumab in Early-Stage NSCLC
A review of recently updated data from KEYNOTE-671, focused on perioperative use of pembrolizumab in early-stage non–small cell lung cancer.
EP. 4: Closing Thoughts on Recent Data in Non–Small Cell Lung Cancer
Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key NSCLC data updates discussed following the 2023 ASCO Annual Meeting.
2 Clarke Drive Cranbury, NJ 08512